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Abstract: Fabry disease is a rare X-linked lysosomal storage disorder caused by a deficiency in -galactosidase A (GLA), 
which catalyzes the hydrolysis of terminal -galactosyl groups from glycosphingolipids, such as globotriaosylceramide 
(Gb3). Many of the mutations in the GLA gene are missense alterations that cause misfolding, decreased stability, and/or 
mistrafficking of this protein. Small molecule compounds that correct the misfolding and mistrafficking, or activate the 
mutant enzyme, may be useful in the treatment of Fabry disease. We have screened a library of approximately 230,000 
compounds using preparations of human recombinant protein and purified coffee bean enzyme in an effort to find activa-
tors and inhibitors of this enzyme. Lansoprazole was identified as a small molecule inhibitor of GLA derived from coffee 
beans (IC50 = 6.4 μM), but no inhibitors or activators were identified for the human enzyme. The screening results indicate 
that human GLA is a difficult target for small molecule inhibition or activation. 
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INTRODUCTION 
  Alpha-galactosidase A (GLA) is a lysosomal enzyme that 
catalyzes the hydrolysis of terminal -galactosyl moieties 
from glycolipids and glycoproteins. Mutations in the GLA 
gene can result in the synthesis of misfolded proteins that are 
retained in the endoplasmic reticulum and degraded prema-
turely. In Fabry disease, a deficiency in GLA results in the 
accumulation of globotriaosylceramide (Gb3), a glycosphin-
golipid, in many cells and organs of the body, including en-
dothelial cells and the smooth muscle cells of blood vessels 
[1]. Patients with Fabry disease present clinically with 
chronic neuronopathic pain, gastrointestinal disturbances, 
angiokeratomata, progressive renal impairment, cardiomy-
opathy, premature myocardial infarctions, and stroke, and 
both life expectancy and quality of life are severely com-
promised. Enzyme replacement therapy (ERT) has been 
available for the treatment of Fabry disease since 2001, and 
is effective in treating the symptoms, but has drawbacks as 
well [2, 3]. In addition to ERT, there is great interest in cor-
recting enzyme misfolding with small molecules, a strategy 
referred to as chemical chaperone therapy (CCT). Chemical 
chaperones are small molecules that bind to mutant proteins 
and assist in their correct folding, maturation, and trafficking 
to the functional site, such as the lysosomes. The effects of 
chemical chaperones have been explored in various lysoso-
mal storage disorders, including Gaucher disease [4-7], 
Pompe disease [8, 9], Tay-Sachs/Sandhoff disease [10], 
GM1-gangliosidosis [11], as well as Fabry disease. A GLA 
inhibitor, 1-deoxygalactonojirimycin (DGJ, marketed as 
Amigal
TM by Amicus Therapeutics, Inc.), is currently being 
studied in a phase 3 clinical trial as a chaperone therapeutic 
agent for Fabry disease [12]. In this chemical chaperone 
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therapy, small molecule inhibitors bind to misfolded proteins 
and correct their folding, maturation and/or trafficking re-
sulting in increased delivery of GLA to lysosomes. Once in 
the lysosomes the inhibitors bound to GLA are displaced by 
the abundant substrates. However, DGJ is an iminosugar 
analog which may not have the desirable drug selectivity, 
and may potentially cause adverse effects. Thus, new im-
proved GLA inhibitors with chaperone activity, as well as 
enzyme activators, are needed for drug development for 
Fabry disease.  
  Several enzyme assays are available for the high 
throughput screening (HTS) of small molecule compound 
libraries against GLA. Chromogenic assays are available that 
use  p-nitrophenol--D-galactopyranoside [13, 14] or 
naphthyl--D-galactopyranoside [15] as substrates. How-
ever, absorbance-based assays are usually less sensitive than 
fluorescence-based assays, and cannot be easily miniaturized 
into a high-density 1536-well plate format for HTS. The pro-
fluorogenic molecule, 4-methylumbelliferyl--D-galactopyr-
anoside (4MU--Gala), is a substrate for GLA, where the 
product of the enzyme reaction emits blue fluorescence at a 
peak of 440 nm upon excitement at 365 nm [16, 17]. Re-
sorufinyl  -D-galactopyranoside (res--Gala) is a red pro-
fluorogenic GLA substrate which excites at 573 nm and 
emits at 610 nm upon galactose cleavage [18, 19]. We report 
here the identification of a novel small molecule GLA in-
hibitor from a compound library screen using these pro-
fluorogenic substrates. GLA from green coffee beans, which 
is readily available, was used in the initial assay develop-
ment and screen validation. Using that protein, we identified 
a novel small molecule inhibitor of GLA, lansoprazole. 
However, in a subsequent screen of 230,000 compounds 
using the human recombinant GLA, we did not find any hits, 
indicating the difficulty of targeting the human enzyme.  
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MATERIALS AND METHODS 
Enzymes, Substrates, and Other Chemicals 
  -Galactosidase A from green coffee beans (G8507, ~10 
units/mg protein) and -glucosidase from rice (G9259, 40-80 
units/mg protein) were purchased from Sigma-Aldrich (St. 
Louis, MO). Glucocerebrosidase was obtained from residual 
solution after clinical infusions of imiglucerase (Cerezyme
®, 
Genzyme Co., Mr = 60,430), with a specific activity of 42.2 
units/mg and 14 units/ml. Recombinant human -
Galactosidase A was also obtained from residual solution 
after clinical infusions (agalsidase beta, marketed as Fabra-
zyme
® by Genzyme Co.). Glycerol was added to these en-
zyme solutions to 30%, and small aliquots were stored at -
80°C. Enzyme activity was found to be stable in these stock 
solutions after storage at -80°C for 2 years.  
 4-methylumbelliferyl--D-galactopyranoside (4MU--
Gala), a blue pro-fluorogenic substrate, and 1-
deoxygalactonojirimycin (DGJ), a known inhibitor of -
galactosidase, were purchased from Sigma-Aldrich, as were 
citric acid, potassium phosphate trihydrate, tween-20, gly-
cine, and sodium hydroxide. Taurocholic acid sodium salt 
was obtained from CalbioChem (a subsidiary of EMD Bio-
science, San Diego, CA). Four compound libraries, the LO-
PAC (Library of Pharmacologically Active Compounds) 
collection, the Prestwick collection, the Spectrum collection, 
and the Tocris collection were purchased from Sigma-
Aldrich, Prestwick Chemicals (Illkirch, France), Micro-
Source Discovery Systems (Gaylordsville, CT) and Tocris 
(Ellisville, MO), respectively. 
Buffers 
  The assay buffer for the -galactosidase and glucocere-
brosidase enzyme assays consisted of 50 mM citric acid, 176 
mM K2PO4, and 0.01% Tween-20 at pH 5.9. The assay 
buffer for -glucosidase was similar, except that it was ti-
trated with K2PO4 to pH 5.0. The buffers were stored at 4°C 
for use up to 6 months. The stop solution consisted of 0.5 M 
sodium hydroxide and 0.5 M glycine at pH 11.6. 
Instruments for Liquid Handling and Plate Detection 
 An  FRD
TM automated microvolume dispensing station 
(Aurora Discovery, San Diego, CA) was used to dispense 
reagents into 1536-well plates at volumes from 1-3 μl. Ini-
tially, the compounds were serially diluted in DMSO in 384-
well plates using a CyBi
®-Well dispensing station with a 
384-well head (Cybio Inc., Woburn, MA), and then refor-
matted into 1536-well plates at 7 μl/well. Nanoliter volumes 
of these compounds were transferred to 1536-well assay 
plates using an automated pin-tool station (Kalypsys, Inc., 
San Diego, CA). A ViewLux
TM CCD-based imaging plate 
reader (PerkinElmer, Boston, MA) was used for fluorescence 
detection at a speed of 30 seconds per plate. A Safire2™ 
monochromator scanning fluorescence plate reader (Tecan 
Group Ltd., Männedorf, Switzerland) was used for determin-
ing the fluorescence excitation and emission spectra. 
Enzyme Kinetics Assay 
  The kinetics assay was carried out in a 384-well plate 
format using 1 nM enzyme with varying concentrations of 
substrate. Initially, 10 μl/well of the varying concentrations 
of substrate were added to the plate. The reaction was initi-
ated by addition of 20 μl/well of enzyme solution. The 4MU-
-Gala stock solution was serially diluted 1:1.5 to give eight 
concentrations. The final concentrations of substrate used in 
the assay were 500, 333, 222, 148, 98.8, 65.8, 43.9, and 29.3 
μM. 30 μl/well of stop solution was added after 2, 4, 6, 8, 10, 
and 12 minute incubation times at RT. A standard curve of 
the free fluorophore, 4-methylumbelliferone (4MU), in the 
same volume of assay buffer and stop solution was generated 
for calculating the enzyme product. The plate was read in the 
ViewLux plate reader at an emission wavelength of 440 nm 
and an excitation wavelength of 365 nm.
  In order to determine the type of inhibition and the inhi-
bition constant of lansoprazole, five enzyme kinetics plots 
were generated in the presence of 80, 40, 20, 10, and 0 μM 
of the inhibitor. The final concentrations of substrate were 
500, 333, 222, 148, 98.8, 65.8, 43.9, 29.3, and 19.5 μM. The 
plate was read in the ViewLux at 2, 4, 6, 8, and 10 minute 
time intervals. As in the above kinetic assay, a standard 
curve of the free fluorophore, 4MU, was generated. The 
plate was read at 440 nm emission upon excitation at 365 
nm. 
qHTS of Compound Collections 
  Quantitative high-throughput screening (qHTS) is a 
method for simultaneously screening large compound librar-
ies at multiple concentrations. The Library of Pharmacologi-
cally Active Compounds (LOPAC) with 1,280 compounds 
from Sigma-Aldrich is commonly used to validate the 
screening assay. Once validated, NCGC’s collection of 
230,000 compounds was screened for GLA activity. The 
compounds in these libraries were serially diluted in DMSO 
at a ratio of 1:5 for up to seven concentrations in 384-well 
plates. Four sets of the inter-plate dilution plates were refor-
matted into one set of 1536-well plates, with compound con-
centrations ranging from 0.29 μM to 10 mM. The pintool 
station was used to transfer 23 nl of compounds in DMSO 
solution to the assay plates with the enzyme solutions. The 
final compound concentrations in a 3 μl assay volume ranged 
from 1.9 nM to 66.7 μM. 
Other Enzyme Assays to Determine Compound Selectiv-
ity 
  The enzyme assays of two other hydrolases, rice -
glucosidase (GAA) and human recombinant glucocerebrosi-
dase (GC) were used for determining the selectivity of the 
active compounds identified from HTS. Both enzyme assays 
employed the similar fluorogenic substrates, 4-
methylumbelliferyl--D-glucopyranoside (4MU--glc) for 
GAA and 4-methylumbelliferyl -D-glucopyranoside (4MU-
-Glc) for GC, which were purchased from Sigma-Aldrich 
(St. Louis, MO). The assays were performed in 1536-well 
black assay plates with 2 μl/well enzyme and 23 nl/well of 
compound in DMSO solution followed by 1 μl/well substrate 
solution. After a 30-minute incubation at the room tempera-
ture (21 °C), 3 μl/well of stop solution was added and the 
assay plates were counted in a Viewlux plate reader for fluo-
rescence intensity at an excitation of 365 nm and emission of 
440 nm. As described previously [7], the final enzyme con-
centration was 8 nM and substrate concentration was 160 
μM for the GAA assay, while the final enzyme and substrate 
concentrations in the GC assay were 1.9 nM and 800 μM, 
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Data Analysis 
  The primary screen data was analyzed and concentration 
responses were fit using a customized software developed 
internally [20, 21]. The results from the assay optimization 
experiments, enzyme kinetics, confirmation experiments, 
and selectivity assays were analyzed with Prism
® (Graphpad, 
San Diego, CA).  
RESULTS AND DISCUSSION 
Screening Assay Optimization 
  The GLA enzyme assay was initially developed using 
commercially available purified enzyme from green coffee 
beans. The classical fluorogenic substrate used, 4MU--
Gala, forms two products, galactose and fluorescent 4MU, 
upon cleavage by GLA. Since this enzyme is naturally found 
in the lysosomes, pH optimization was first performed. A pH 
titration revealed an optimal pH of 5.9 (Fig. 1a) for this en-
zyme assay, and this buffer pH was used for subsequent ex-
periments. An addition of stop solution after the enzyme 
reaction raised the final pH in assay plates to 10 for optimal 
fluorescence detection, because the 4MU fluorophore has a 
pKa of 7.8 and its fluorescence intensity is not favorably de-
tected below this pKa value. 
  While sodium taurocholate is routinely used in the GLA 
assay buffer [22], its optimal concentration has not been 
well-established. It is a bile salt that is required for the activ-
ity of certain lysosomal enzymes [23]. A titration of sodium 
taurocholate was performed in this enzyme assay to establish 
its optimal concentration. Unexpectedly, we found that so-
dium taurocholate decreased the GLA activity at all the con-
centrations tested (ranging from 0.15 to 40 mM) (Fig. 1b), 
while enzyme activity was quite high without this bile salt. 
This result contrasts with the sodium taurocholate depend-
ence of glucocerebrosidase, another lysosomal enzyme, 
which shows almost no enzyme activity in the absence of 
this bile salt [7]. Thus, sodium taurocholate was eliminated 
from the GLA assay buffer. 
  The enzyme concentration-response was also measured 
at a fixed substrate concentration in order to establish the 
optimal enzyme concentration for compound screening. It 
showed a nearly linear response from 0.125 nM to 4 nM 
GLA (Fig. 1c). Based on this result, 1 nM enzyme was se-
lected for the assay because the fluorescence intensity 
(4000 RFU) was adequate, while the substrate consumption 
was under 10% at this enzyme concentration. An incubation 
of 20 minutes at RT was selected because the enzyme activ-
ity was linear during a 40 minute incubation time (data not 
shown).  
  DMSO tolerance of this enzyme assay was also evalu-
ated, as it is the solvent used for dissolving library com-
pounds. It was found that the enzyme activity slightly de-
creased with increasing DMSO concentrations (Fig. 1d). The 
enzyme activity was not significantly decreased at the 0.76% 
DMSO concentration used for the compound screens. 
Enzyme Kinetics 
  The enzyme kinetics experiments were performed using 
1 nM enzyme with substrate concentrations ranging from 30 
to 500 uM. It was found that the Km was 144 μM and the 
Vmax 5.74 pmol/min at the optimal pH of 5.9 (Fig. 2a). This 
is similar to the value of 239 μM, determined with the same 
substrate, but at pH 6.5 [24]. In addition, a kinetic analysis 
was done at the previously used pH of 4.5 [25], and the Km 
and Vmax were found to be 102 μM and 2.76 pmol/min, re-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Optimization of the GLA assay. (a) GLA activity at different pH values. The optimal pH was 5.9. (b) Effect of sodium taurocholate. 
GLA activity decreased with increasing concentrations of sodium taurocholate. (c) Enzyme concentration-response. The enzyme activity 
increased nearly linearly from 0.125 to 4 nM GLA. (d) DMSO tolerance. Fluorescence slightly decreased as DMSO concentration increased. 70    Current Chemical Genomics, 2010, Volume 4  Motabar et al. 
spectively (Fig. 2b). The Km values were similar for the two 
assays, while the rate of substrate cleavage was about two 
fold greater at pH 5.9 than at pH 4.5. 40 μM of 4MU--Gala 
was chosen as the substrate concentration for this assay, as it 
was less than the Km value (important for compound screen-
ing sensitivity) and gave sufficient fluorescence. 
  Thus, for compound screening, 1 nM GLA and 40 μM 
4MU--Gala were chosen as the enzyme and substrate con-
centrations, respectively. The assay was performed at pH 5.9 
with 20 minutes incubation at RT.  
IC50 Determination of a Known GLA Inhibitor 
  For further assay validation, the activity of a known in-
hibitor, 1-deoxygalactonojirimycin (DGJ), was evaluated 
using this enzyme assay. The IC50 value of this known in-
hibitor was 5.6 nM in this enzyme assay (Fig. 3), which is 
similar to the reported IC50 value of 3 nM [26]. This com-
pound was used as an internal control in the subsequent 
compound screening experiments. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Concentration response of the known GLA inhibitor, DGJ. 
The substrate concentration was 40 μM and the enzyme concentra-
tion was 1 nM. The IC50 was found to be 5.6 nM.  
 
Screen Validation  
  In order to test the performance of this enzyme assay for 
compound screening, we used several small collections of 
known bioactive compounds, including the LOPAC, Prest-
wick, Spectrum, and the Tocris-Timtec libraries. In a DMSO 
plate test without compounds, the signal-to-basal ratio from 
the control plate was 32.6 fold, and the CV and Z’ factor 
were 8.1% and 0.76, respectively (Fig. 4). These results indi-
cated that this GLA enzyme assay in the 1536-well plate 
format was robust and suitable for HTS. The qHTS results 
using the bioactive 6,160 compound set revealed 31 initial 
“hits”, with a hit rate of approximately 0.50%. This is in the 
range of the commonly desired 0.1 to 1% hit rate for HTS. 
However, most of these hits were weak, and were not pur-
sued (Pubchem assay ID: 998). Three of these compounds 
showed relatively high inhibitory activity against GLA, and 
were chosen for follow-up experiments. These compounds 
were lansoprazole, merbromin, and phenylmercuric acetate.  
 
 
 
 
 
 
 
 
Fig. (4). Scatter plot of the results from the control DMSO plate 
screen. The signal-to-basal ratio was 32.6 with a CV of 8.1%, and 
the Z’ factor was 0.76. 
 
Hit Confirmation and Compound Characterization 
  Fresh samples of the three hits from the primary screen 
were obtained, and their inhibitory activities against GLA 
were confirmed in the same enzyme assay. To characterize 
the selectivity of these compounds, they were tested using 
other lysosomal enzyme assays. Rice -glucosidase (GAA) 
and human recombinant glucocerebrosidase (GC) were 
tested in similar fluorogenic enzyme assay formats. While all 
three compounds had little effect on GAA, they exhibited 
inhibitory effects against GC, as well as GLA. Among the 
three compounds, only lansoprazole showed selectivity for 
GLA over GC (Fig. 5), as its IC50 for GLA was about 19 
times more potent than that for GC (IC50 for GLA was 6.4 
μM and IC50 for GC was 122 μM). The other two com-
pounds were not selective for GLA, as the activity of mer-
 
 
 
 
 
 
 
 
 
 
Fig. (2). Enzyme kinetics. (a) At the optimal pH of 5.9, the enzyme had a Km of 144 μM and a Vmax of 5.74 pmol/min. (b) At an acidic 
lysosomal pH of 4.5, the enzyme had a Km of 102 μM and a Vmax of 2.76 pmol/min. High Throughput Screening for Inhibitors of Alpha-Galactosidase  Current Chemical Genomics, 2010, Volume 4    71 
bromin was 0.63 μM in the GC assay vs. 1.38 μM in the 
GLA assay, and the IC50  of phenylmercuric acetate was 
0.082 μM in the GC assay vs. 7.42 μM in the GLA assay 
(Fig. 5).  
  To characterize the mechanism of inhibition on GLA, 
varying concentrations of lansoprazole were tested in the 
GLA kinetics assay. A Lineweaver-burk plot of the results 
showed that the linear regression curves of the reciprocal 
data neither converged on the y-axis (competitive inhibition) 
or the x-axis (non-competitive inhibition) (Fig. 6). The cross 
point of these linear regression curves was in between the y-
axis and x-axis, indicating a mixed type of inhibition. Both 
the Km and Vmax of GLA were affected in the presence of 
varying concentrations of this inhibitor. The Ki of lansopra-
zole was calculated as 5.5 μM. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Lineweaver-burk plot of the kinetic data, where various 
Km and Vmax values were obtained in the presence of different con-
centrations of inhibitor. The compound showed mixed inhibition 
and the inhibition constant (Ki) was 5.5 μM. 
 
  Lansoprazole is an FDA approved drug used to treat pep-
tic ulcers and gastroesophageal reflux disease. It inhibits the 
proton-pump of gastric parietal cells, and thus decreases the 
amount of gastric acid secretion in the stomach. It has not 
previously been reported to have inhibitory activity on GLA.  
HTS of 230,000 Compounds Using the Human Recombi-
nant GLA  
  Once human recombinant GLA became available for 
screening, the enzyme assay was optimized once again, as 
described above. A screen of 230,000 diverse compounds 
was carried out using human enzyme in the qHTS format. 
The primary screen results yielded 136 hits with a hit rate of 
0.06%, a rate that was quite low. All of the primary results as 
well as the assay conditions have been deposited into Pub-
chem (Assay ID: 1467). Further confirmation and counter 
screen tests of these primary hits revealed that there were no 
selective and relatively potent (IC50 < 50 M) GLA inhibi-
tors against the human enzyme. In an additional effort to find 
new GLA inhibitors for the human enzyme, we developed an 
assay using GLA in human spleen homogenate as the en-
zyme source. This assay used the native enzyme from human 
tissue, since the GLA enzyme should be in its native con-
formation and in a physiologically relevant environment 
with subunits and co-factors. A qHTS was carried out with 
this assay using the same compound library and 194 primary 
hits were found, with a hit rate of 0.08% (Assay ID: 2107). 
No relatively potent GLA inhibitor (IC50 < 50 M) remained 
after the confirmation and selectivity tests. In both screens, 
the previously identified coffee bean GLA inhibitor, lanso-
prazole, was not active with the human enzyme, and no en-
zyme activators were found as well. These negative screen-
ing results for the human GLA preparation were in contrast 
to screens with other lysosomal enzymes, including human 
glucocerebrosidase and -glucosidase, where potent activa-
tors and inhibitors were identified [7, 27]. The difficulty in 
identifying activators and inhibitors of human GLA indicates 
that this enzyme might be a difficult or “undruggable” target 
for small molecules. It should be noted that the compound 
libraries had little diversity in chemotypes that mimic sugars 
such as DGJ. 
  Coffee bean GLA has 59% homology to the recombinant 
human enzyme [28]. It is known that two enzymes can have 
similar catalytic mechanisms and active sites despite a mod-
est similarity in primary sequence, as is the case with many 
other proteins, such as chymotrypsin and subtilisin [29]. De-
spite the functional similarity of coffee bean and human 
GLAs, species differences in small molecule inhibition of 
proteins should not be unexpected, as even closely related 
 
 
 
 
 
 
 
 
 
Fig. (5). Inhibition curves of the three compounds that were able to inhibit GLA. Inhibition curves for -glucosidase and glucocerebrosidase 
are also shown. (a) Lansoprazole’s potency (IC50 = 6.4 μM) was about 19 times greater against GLA than GC. It did not inhibit GAA. (b) 
Merbromin was more potent against GC than GLA. It slightly inhibited GAA. (c) Phenylmercuric acetate was significantly more potent 
against GC than GLA. It did not inhibit GAA. 72    Current Chemical Genomics, 2010, Volume 4  Motabar et al. 
species often have important activity differences. For exam-
ple, DT-diaphorase, an enzyme involved in activating anti-
tumor compounds, responded differently to a compound de-
pending on the source of this enzyme. It was found that hu-
man DT-diaphorase was not as effective as rat DT-
diaphorase in activating cytotoxic antitumor drugs [30-32]. 
However, replacing one amino acid residue in the human 
with that present in the rat enhanced the effectiveness of the 
compound [30]. This indicates that a slight difference in 
amino acid sequence of an enzyme can cause a significant 
change in compound activity. Conversely, it has been ob-
served that human TRPA1, a cation channel implicated
  in 
pain and neurogenic inflammation, is inhibited by certain 
trichloro(sulfanyl)ethyl benzamides, while these same com-
pounds are inactive or serve as activators for rat TRPA1 [33, 
34].  
  An amino acid sequence analysis shows that coffee bean 
GLA shares 36% identity and 59% homlogy with human 
GLA [28]. There is a conserved CEW sequence in the hu-
man, coffee, and rice GLAs, as well as in other organisms 
(human residues 203-205), which is an important part of the 
active site in the human protein structure (Fig. 7 and Suppl 
Fig. 1). However, the crystal structure of rice GLA (PDB 
code: 1UAS) reveals that this conserved sequence does not 
support the same structural role as it does in the human pro-
tein structure (PDB code: 1R47). Tryptophan 205 is buried 
in the human protein structure, but its equivalent amino acid 
in the rice sequence is exposed to solvent. Using the rice 
template as a model for the coffee bean’s protein structure, it 
might be hypothesized that this tryptophan provides support 
(a hot-spot) for lansoprazole binding, while its absence in the 
human protein active site explains why the observed activity 
profiles are so different between the two proteins [35]. Com-
paring these two proteins should give better insight into what 
makes one enzyme “druggable” and another not, and it may 
be that the difference in hydrophobic surface area provided 
by the coffee bean’s solvent-exposed tryptophan provides 
the crucial difference. 
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